APYX Quote, Financials, Valuation and Earnings

electroCore has a net margin of -32.54% compared to Apyx Medical's net margin of -45.81%. Apyx Medical's return on equity of -133.56% beat electroCore's return on equity of -147.07%.

Apyx Medical has a consensus price target of $2.88, signalling upside risk potential of 222.58%. On the other hand electroCore has an analysts' consensus of $25.20 which suggests that it could grow by 215%. Given that Apyx Medical has higher upside potential than electroCore, analysts believe Apyx Medical is more attractive than electroCore.

Apyx Medical has a beta of 1.184, which suggesting that the stock is 18.437% more volatile than S&P 500. In comparison electroCore has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.612%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are larger than electroCore quarterly revenues of $7M. Apyx Medical's net income of -$4.6M is lower than electroCore's net income of -$3.2M. Notably, Apyx Medical's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 2.38x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

Paragon 28 has a net margin of -32.54% compared to Apyx Medical's net margin of -15.5%. Apyx Medical's return on equity of -133.56% beat Paragon 28's return on equity of -36.38%.

Apyx Medical has a consensus price target of $2.88, signalling upside risk potential of 222.58%. On the other hand Paragon 28 has an analysts' consensus of $14.50 which suggests that it could grow by 11.45%. Given that Apyx Medical has higher upside potential than Paragon 28, analysts believe Apyx Medical is more attractive than Paragon 28.

Apyx Medical has a beta of 1.184, which suggesting that the stock is 18.437% more volatile than S&P 500. In comparison Paragon 28 has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Paragon 28 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Paragon 28 pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are smaller than Paragon 28 quarterly revenues of $71.7M. Apyx Medical's net income of -$4.6M is higher than Paragon 28's net income of -$11.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Paragon 28's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 4.23x for Paragon 28. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -32.54% compared to Apyx Medical's net margin of -17.66%. Apyx Medical's return on equity of -133.56% beat KORU Medical Systems's return on equity of -32.71%.

Apyx Medical has a consensus price target of $2.88, signalling upside risk potential of 222.58%. On the other hand KORU Medical Systems has an analysts' consensus of $5.70 which suggests that it could grow by 102.13%. Given that Apyx Medical has higher upside potential than KORU Medical Systems, analysts believe Apyx Medical is more attractive than KORU Medical Systems.

Apyx Medical has a beta of 1.184, which suggesting that the stock is 18.437% more volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.468%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are larger than KORU Medical Systems quarterly revenues of $8.8M. Apyx Medical's net income of -$4.6M is lower than KORU Medical Systems's net income of -$1.6M. Notably, Apyx Medical's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 3.84x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Owlet has a net margin of -32.54% compared to Apyx Medical's net margin of -44.19%. Apyx Medical's return on equity of -133.56% beat Owlet's return on equity of --.

Apyx Medical has a consensus price target of $2.88, signalling upside risk potential of 222.58%. On the other hand Owlet has an analysts' consensus of $11.75 which suggests that it could grow by 173.89%. Given that Apyx Medical has higher upside potential than Owlet, analysts believe Apyx Medical is more attractive than Owlet.

Apyx Medical has a beta of 1.184, which suggesting that the stock is 18.437% more volatile than S&P 500. In comparison Owlet has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Owlet pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $14.2M, which are smaller than Owlet quarterly revenues of $20.5M. Apyx Medical's net income of -$4.6M is higher than Owlet's net income of -$9.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Owlet's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 0.92x versus 0.61x for Owlet. Usually stocks with elevated PS ratios are considered overvalued.